Intracellular Adhesion Molecule‐1 Improves Responsiveness to Immune Checkpoint Inhibitor by Activating CD8<sup>+</sup> T Cells

Se‐Hoon Lee(Samsung Medical Center), Kyoung Wan Yoon(Hoseo University)

Advanced Science

April 25, 2023

10.1002/advs.202204378

Cited by 23

Related Papers

Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer

|Journal of Clinical Oncology|2020|1.2k

Perioperative Pembrolizumab for Early-Stage Non–Small-Cell Lung Cancer

|New England Journal of Medicine|2023|1k

Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort

|Journal of Clinical Oncology|2016|859

Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial

|The Lancet|2024|233

HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor–Mutated Non–Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy

|Journal of Clinical Oncology|2023|224